DE
40
-8
AIZ
57
-2
AZO
50
-6
HOG
34
-2
LRCX
42
-16
RL
75
-4
KLAC
47
-20
NVDA
57
-8
SPG
63
2
ETN
76
-4
TGT
52
2
SYF
85
-3
MMM
45
-2
SRE
63
2
WYNN
44
-8
ILMN
65
-3
DVN
43
3
PCAR
58
-4
FCX
61
-5
LH
36
-4
DE
40
-8
AIZ
57
-2
AZO
50
-6
HOG
34
-2
LRCX
42
-16
RL
75
-4
KLAC
47
-20
NVDA
57
-8
SPG
63
2
ETN
76
-4
TGT
52
2
SYF
85
-3
MMM
45
-2
SRE
63
2
WYNN
44
-8
ILMN
65
-3
DVN
43
3
PCAR
58
-4
FCX
61
-5
LH
36
-4
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Multimillionaire Trader Reveals His #1 Gold Pick

Click here to learn more about this game-changing opportunity.
Buy
56

PTGX
Protagonist Therapeutics

Last Price:
47.70
Seasonality Move:
13.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Urgent: The Biggest Gold Bull Market in History Is Here

Click here for urgent details - don't miss out.

Protagonist Therapeutics Price Quote

$47.70
+0.06 (+0.13%)
(Updated: October 16, 2024 at 10:10 AM ET)

Protagonist Therapeutics Key Stats

Buy
56
Protagonist Therapeutics (PTGX) is a Buy
Day range:
$46.59 - $48.32
52-week range:
$13.72 - $48.32
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
5.18%
Volume:
598.5K
Avg. volume:
685.7K
1-year change:
208.55%
Market cap:
$2.8B
Revenue:
$60M
EPS:
$2.62

How Much Does Protagonist Therapeutics Make?

Data Unavailable

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $231.5M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $45.6M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$156.9M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 41.77%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 37.73%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 41.77%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -21.11%
Revenue: 0% -37.5%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 52.13
Upside from Last Price: 9.41%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    103.8M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders